Valion Bio, Inc. Operating Cash Flow
Valion Bio, Inc. (VBIO) reported Operating Cash Flow of -$10.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Valion Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$5.28M.
- Valion Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.01M.
- Valion Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.29M.
- Valion Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.00M.
- Valion Bio, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$7.00M.
- Valion Bio, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$5.72M.
- Valion Bio, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$8.51M.
- Valion Bio, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$8.92M.
| Period end | Net Cash Provided by (Used in) Operating Activities 1 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$5.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$10.29M 10-Q · filed 2026-08-14 | -$12.58M derived: sum of 3 quarters · filed 2026-08-14 | -$14.57M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$5.01M 10-Q · filed 2026-05-14 | -$7.30M derived: sum of 2 quarters · filed 2026-05-14 | -$9.29M derived: sum of 3 quarters · filed 2026-05-14 | -$11.12M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | -$2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$4.28M derived: sum of 2 quarters · filed 2026-03-30 | -$6.11M derived: sum of 3 quarters · filed 2026-08-14 | -$7.00M 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$3.82M derived: sum of 2 quarters · filed 2026-08-14 | -$4.71M 10-Q · filed 2025-11-14 | -$6.08M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.72M 10-Q · filed 2026-08-14 | -$4.08M derived: sum of 3 quarters · filed 2026-08-14 | -$5.49M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$889.00K 10-Q · filed 2026-05-14 | -$2.25M derived: sum of 2 quarters · filed 2026-05-14 | -$3.66M derived: sum of 3 quarters · filed 2026-05-14 | -$4.95M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$2.77M derived: sum of 2 quarters · filed 2026-03-30 | -$4.06M derived: sum of 3 quarters · filed 2026-03-30 | -$5.72M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$2.69M derived: sum of 2 quarters · filed 2025-11-14 | -$4.36M 10-Q · filed 2025-11-14 | -$6.13M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.95M 10-Q · filed 2025-08-14 | -$4.73M derived: sum of 3 quarters · filed 2025-08-14 | -$6.60M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$1.67M 10-Q · filed 2025-05-15 | -$3.44M derived: sum of 2 quarters · filed 2025-05-15 | -$5.31M derived: sum of 3 quarters · filed 2025-05-15 | -$7.75M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$3.65M derived: sum of 2 quarters · filed 2025-03-21 | -$6.08M derived: sum of 3 quarters · filed 2025-03-21 | -$8.51M 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$4.31M derived: sum of 2 quarters · filed 2024-11-14 | -$6.74M 10-Q · filed 2024-11-14 | -$8.96M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$4.87M 10-Q · filed 2024-08-14 | -$7.09M derived: sum of 3 quarters · filed 2024-08-14 | -$9.87M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$2.43M 10-Q · filed 2024-05-15 | -$4.65M derived: sum of 2 quarters · filed 2024-05-15 | -$7.42M derived: sum of 3 quarters · filed 2024-05-15 | -$9.18M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$5.00M derived: sum of 2 quarters · filed 2024-03-25 | -$6.75M derived: sum of 3 quarters · filed 2024-03-25 | -$8.92M 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$4.52M derived: sum of 2 quarters · filed 2023-11-14 | -$6.69M 10-Q · filed 2023-11-14 | -$9.45M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$3.92M 10-Q · filed 2023-08-14 | -$6.68M derived: sum of 3 quarters · filed 2023-08-14 | -$8.32M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$2.17M 10-Q · filed 2023-05-15 | -$4.93M derived: sum of 2 quarters · filed 2023-05-15 | -$6.57M derived: sum of 3 quarters · filed 2023-05-15 | -$7.12M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2022-01-31 | -$2.17M 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | -$2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$4.40M derived: sum of 2 quarters · filed 2023-03-31 | -$4.95M derived: sum of 3 quarters · filed 2023-03-31 | -$5.61M 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.19M derived: sum of 2 quarters · filed 2022-11-14 | -$2.85M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$543.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$1.21M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$665.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |